Short Communication: Dynamic Constraints on the Second Phase Compartment of HIV-Infected Cells
Open Access
- 1 July 2011
- journal article
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 27 (7) , 759-761
Abstract
The cells responsible for the second phase decay of HIV-1 viremia following the initiation of antiretroviral therapy have yet to be identified. A dynamic model that considers where drugs act in the virus life cycle places constraints on candidate cell types. In this regard, the rapid drop in viremia in patients starting regimens containing the integrase inhibitor raltegravir is of particular interest. We show here that the time delay between reverse transcription and integration is short in differentiated macrophages, making these cells poor candidates for the second phase compartment under the assumptions of standard models of viral dynamics.Keywords
This publication has 19 references indexed in Scilit:
- Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapyProceedings of the National Academy of Sciences, 2009
- Characterization of the Early Steps of Infection of Primary Blood Monocytes by Human Immunodeficiency Virus Type 1Journal of Virology, 2008
- Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugsNature Medicine, 2008
- Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycleProceedings of the National Academy of Sciences, 2008
- Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phaseAIDS, 2007
- Decay characteristics of HIV-1-infected compartments during combination therapyNature, 1997
- HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation TimeScience, 1996
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structureCell, 1990